Eculizumab, within its marketing authorisation, is recommended for funding for treating atypical haemolytic uraemic syndrome, only if all the following arrangements are in place:
coordination of eculizumab use through an expert centre
monitoring systems to record the number of people with a diagnosis of atypical haemolytic uraemic syndrome and the number who have eculizumab, and the dose and duration of treatment
a national protocol for starting and stopping eculizumab for clinical reasons
a research programme with robust methods to evaluate when stopping treatment or dose adjustment might occur.